Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Cellectis SA (CLLS) Stock Price & Analysis
863 Followers
CLLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.96 - $3.77
Previous Close$2.03
Volume11.77K
Average Volume (3M)56.99K
Market Cap
$144.10M
Enterprise Value$58.84M
Total Cash (Recent Filing)$136.71M
Total Debt (Recent Filing)$51.45M
Price to Earnings (P/E)―
Beta3.75
Next Earnings
Aug 01, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding71,751,201
10 Day Avg. Volume83,815
30 Day Avg. Volume56,989
Standard Deviation0.33
R-Squared0.24
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.61
Price to Sales (P/S)7.07
Price to Cash Flow (P/CF)0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue37.60
Enterprise Value/Gross Profit3.27K
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$8.25Price Target Upside306.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cellectis SA News
PremiumCompany Announcements
Cellectis Shareholders Approve Key ResolutionsPremiumCompany Announcements
Cellectis Shareholders Support Management’s Vision
PremiumCompany Announcements
Cellectis Reveals Advances in Gene Editing Efficiency
PremiumCompany Announcements
Cellectis Pioneers Non-Viral Gene Therapy for SCD
Ownership Overview
0.00%
Insiders
3.91% Mutual Funds
10.20% Other Institutional Investors
85.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $0.96 and its highest was $3.77 in the past 12 months.
What is Cellectis SA’s market cap?
Currently, no data Available
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 28, 2024. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.41.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -$0.29.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at N/A.
---
Cellectis SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (306.40% Upside)
$8.25 (306.40% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.57%
12-Months-Change
Fundamentals
Return on Equity
-76.82%
Trailing 12-Months
Asset Growth
40.99%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
---
CLLS Earnings Call
Q1 2024
0:00 / 0:00
---
CLLS Stock 12 Month Forecast
Average Price Target
$8.25
▲(306.40% Upside)
Technical Analysis
Best Analysts Covering CLLS
1 Year
1 Year Success Rate
10/27 ratings generated profit
1 Year Average Return
-20.41%
reiterated a buy rating last month
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of -20.41% per trade.
---